BioWales 2004 shows the fire in the Welsh medical technology industry
This article was originally published in Clinica
Changes are afoot in the operational, regulatory and investment environments of the UK healthcare industry, which are necessary for the appropriate development of the medical technology industry. But far from any misconceptions of underdevelopment, the Welsh industry is aiming to ensure that such changes can only help it build on proven successes, Bernard Murphy learnt at the BioWales 2004 conference, hosted recently by the Welsh Development Agency, in Cardiff.
You may also be interested in...
Pharma manufacturing is operating well below normal levels in India, disrupted by labor absenteeism and supply chain issues amid the ongoing lock-down in the country, though the government is actively engaged in addressing bottlenecks. A speedy recovery is vital not just for domestic supplies.
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.